616 related articles for article (PubMed ID: 28526278)
1. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps.
Bachert C; Gevaert P; Hellings P
J Allergy Clin Immunol Pract; 2017; 5(6):1512-1516. PubMed ID: 28526278
[TBL] [Abstract][Full Text] [Related]
2. Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
Kartush AG; Schumacher JK; Shah R; Patadia MO
Am J Rhinol Allergy; 2019 Mar; 33(2):203-211. PubMed ID: 30587005
[TBL] [Abstract][Full Text] [Related]
3. Emerging biologics for the treatment of chronic rhinosinusitis.
Pauwels B; Jonstam K; Bachert C
Expert Rev Clin Immunol; 2015 Mar; 11(3):349-61. PubMed ID: 25651905
[TBL] [Abstract][Full Text] [Related]
4. [Progress of monoclonal antibody treatment for chronic rhinosinusitis with or without nasal polyps].
Chen YJ; Chai XB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 May; 32(10):789-793. PubMed ID: 29873221
[TBL] [Abstract][Full Text] [Related]
5. Biologics for chronic rhinosinusitis with nasal polyps.
Bachert C; Zhang N; Cavaliere C; Weiping W; Gevaert E; Krysko O
J Allergy Clin Immunol; 2020 Mar; 145(3):725-739. PubMed ID: 32145872
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
8. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
Rivero A; Liang J
Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
[TBL] [Abstract][Full Text] [Related]
9. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
10. [Chronic rhinosinusitis with nasal polyps : is there a place for monoclonal antibodies in 2020 ?].
Clottu A; Reinhard A; Comte D
Rev Med Suisse; 2021 Jan; 17(720-1):13-17. PubMed ID: 33443824
[TBL] [Abstract][Full Text] [Related]
11. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
Bachert C; Zhang L; Gevaert P
J Allergy Clin Immunol; 2015 Dec; 136(6):1431-1440. PubMed ID: 26654192
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of omalizumab in the treatment of chronic rhinosinusitis with nasal polyps: a discussion of 2 refractory cases].
Jandus P; Harr T; Soyka MB; Landis BN
Rev Med Suisse; 2019 Oct; 15(665):1748-1751. PubMed ID: 31580018
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials.
Bachert C; Corren J; Lee SE; Zhang H; Harel S; Cunoosamy D; Khan AH; Jacob-Nara JA; Siddiqui S; Nash S; Rowe PJ; Deniz Y
Int Forum Allergy Rhinol; 2022 Sep; 12(9):1191-1195. PubMed ID: 34970860
[No Abstract] [Full Text] [Related]
14. Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents' efficacy.
Papacharalampous GX; Constantinidis J; Fotiadis G; Zhang N; Bachert C; Katotomichelakis M
Int Forum Allergy Rhinol; 2024 Jan; 14(1):96-109. PubMed ID: 37394893
[TBL] [Abstract][Full Text] [Related]
15. Targeting IL-25 as a novel therapy in chronic rhinosinusitis with nasal polyps.
Lee M; Kim DW; Shin HW
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):17-22. PubMed ID: 27870664
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
18. An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma.
Castagnoli R; Licari A; Brambilla I; Tosca M; Ciprandi G; Marseglia GL
Expert Rev Respir Med; 2020 Dec; 14(12):1197-1205. PubMed ID: 32875924
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives.
Okano M; Kanai K; Oka A
Auris Nasus Larynx; 2024 Apr; 51(2):371-378. PubMed ID: 37743131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
